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Using internal fiducial markers and electronic portal imaging (EPI) to realign pa-
tients has been shown to significantly reduce positioning uncertainties in prostate
radiation treatment. This creates the possibility of decreasing the planning target
volume (PTV) margin added on the clinical target volume (CTV), which in turn
may allow for dose escalation. We compared the outcome of two plans: 70 Gy/35
fx, 10-mm PTV margin without patient realignment (Reference Plan) and 78 Gy/
39 fx, 5-mm PTV margin with patient realignment (Escalated Plan). Four-field-
oblique (gantry angles 35°, 90°, 270°, 325°) beam arrangement was used. Monte
Carlo code was used to simulate the daily organ motion. Dose to each organ was
calculated. Tumor control probability (TCP) and the effective dose to critical or-
gans (D
eff
) were calculated using the biologically normalized dose-volume
histograms. By comparing the biological factors, we found that the prescription
dose can be escalated to 78 Gy/39 fx with a 5-mm PTV margin when using inter-
nal fiducial markers and EPI. Based on the available dose-response data for
intermediate risk prostate patients, this will result in a 20% increase of local con-
trol and significantly reduced rectal complications provided that less serial
dose-volume behavior of rectum is proven.
PACS number: 87.50.-a
Key words: Patient realignment, organ motion simulation, prostate cancer dose
escalation, dose-population histogram, biological factors
I. INTRODUCTION
Planning target volume (PTV) margins are conventionally added to the clinical target volume
(CTV) to account for uncertainties associated with organ motion and day-to-day setup varia-
tion. These margins can be uniform or asymmetric, depending on organ motion and risk of
toxicity to surrounding organs. There appears to be a certain degree of variation among cancer
centers regarding the prostate PTV definition.(1–6) Commonly, the margin is approximately 1
cm with a smaller posterior margin to achieve better rectal sparing. A more generic approach
has been suggested by van Herk,(7) who proposed linking the PTV margin with systematic and
random errors.
PTV margins can be reduced if better tumor targeting is achieved, for which various meth-
ods have been suggested. Patient realignment alone is adequate if interfraction motion is
considerable while intrafraction motion is not as significant, for example, the prostate. This is
in contrast to gating techniques, when intrafraction motion is significant, for example, the
lung. Realigning the patient(8) allows us to reduce the PTV margin while keeping the CTV
adequately covered, sparing normal tissues and potentially escalating the dose.
In our previous work,(9) we tested PTV margins from 2 mm to 12 mm using three real
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patient anatomies with full (no realignment) or reduced (daily online realignment) uncertain-
ties. An online realignment(8) using fiducial markers implanted in the prostate, in combination
with daily electronic portal image (EPI) acquisition prior to each fraction, was simulated. We
assumed that only lateral images were taken to localize the prostate, following the Princess
Margaret Hospital protocol.(8) Of all the considered margins, 4-mm and 6-mm margins were
deemed acceptable for dose escalation up to 74 Gy or 78 Gy while keeping rectal toxicity at the
level associated with the larger PTV and without realignment (full uncertainties).
In this paper, we extend this study to ensure that these smaller margins will be applicable to
a larger group of patients. We also specifically address the importance of dose-volume effects
in the rectum for dose escalation with patient realignment. This topic has become debatable
recently because evidence pointing toward a more parallel behavior(9,10) for rectal toxicity has
been presented. This is in contrast to previously assumed serial behavior.(11,12) There may also
be a difference in the volume dependence, depending on the severity of the rectal toxicity.
II. METHODS
A. Treatment planning
The purpose of this study was to investigate whether PTV margins can be safely decreased, in
order to perform dose escalation. The CTV was defined as the prostate; seminal vesicles and
pelvic lymph nodes were not included. The rectum and bladder were considered organs at risk
(OARs). CT scans of 20 prostate cancer patients were included in the study. The prostate was
contoured by the treating radiation oncologist. Both the bladder and rectum were contoured as
solid organs. The rectum was contoured from the anal verge to the level where it becomes the
sigmoid colon. Treatment planning was performed on the Eclipse treatment-planning system
(Varian, Palo Alto, CA) for a Varian EX 120 multileaf collimator (MLC) linear accelerator.
Three-dimensional uniform margins of 10 mm and 5 mm were automatically added to the
prostate (CTV) to obtain the PTVs. In this paper, a 10-mm PTV margin with a prescription
dose of 70 Gy/35 fx and no patient realignment is referred to as a Reference Plan. A treatment
plan with a 5-mm margin with a prescribed dose of 78 Gy/39 fx with patient realignment is
called an Escalated Plan.
The beam arrangement was a four-field setup, using two lateral and two anterior-oblique
fields with gantry angles of 35°, 90°, 270°, and 325°.(1) The MLC leaf positions were manually
adjusted to cover the entire PTV with the 95% isodose surface.
B. Organ motion simulation and dose calculation
A Monte Carlo code running in the MATLAB (MathWorks, Natick, MA) environment(13) was
developed to simulate geometric uncertainties during the treatment on a fraction-by-fraction
basis. The code simulates organ motion with the following assumptions: (1) organ deformation
and rotation are not considered, and (2) relative positions between the prostate, rectum, and
bladder do not change. Geometric uncertainty was separated into systematic and random ele-
ments, which were assumed to obey a Gaussian distribution.(7) The overall displacement of a
single fraction was modeled as a sum of systematic and random components. For a specific
virtual patient, the systematic uncertainty was sampled once and was kept constant for each
fraction through the course of treatment. Random uncertainty was sampled for each fraction.
The standard deviations associated with both systematic and random uncertainties used in
this simulation were taken from the published literature (Table 1). For the treatment without
patient realignment, that is, the full uncertainty situation, the standard deviations were taken
from Table 1 of the paper by van Herk et al.(7) The reduced uncertainty data (i.e., after online
correction with a 3-mm action level) were taken from Table 3 of the paper by Chung et al.,(8)
40 Zhang et al.: PTV margin for dose escalated radiation therapy... 40
Journal of Applied Clinical Medical Physics, Vol. 7, No. 2, Spring 2006
the “center of mass” data. Two hundred histories were calculated for each treatment plan with
a calculation time of 6 h to 7 h on a Pentium IV 2.66 GHz PC. This number of histories was
demonstrated to be sufficient to establish confidence limits within a reasonable duration of
calculation.
Table 1. The standard deviations of geometric uncertainties used in the simulations
The dose distribution from the treatment-planning system was used to calculate the dose
delivered every fraction. In the following sections, any results referred to as “static” were
calculated without organ motion simulations; for example, the dose to each organ is the same
as the planning dose for each fraction. If the dose distribution or a specific parameter is re-
ferred to as “blurred,” this means that the results were obtained with organ motion simulation.
Dose from each fraction was accumulated on a voxel-by-voxel basis for each organ.(14,15)
For each voxel, dose was converted to the normalized total dose (NTD),(16) which is the bio-
logically equivalent dose in 2 Gy/fraction. The formula used to convert dose to one voxel for
the ith fraction to NTD is
(1)
where α and β are the parameters in the linear-quadratic model. The values are listed in
Table 2.
Table 2. Parameters used in biological factor calculation(11,12,17–19)
C. Biological factor calculation
Each plan was evaluated for both local control and toxicity. This was done by calculating
biological indices: TCP(17,18) and D
eff
 (isoeffective dose to whole volume).(11,12,19,20) Note that
the TCP has to be defined for the gross tumor volume (GTV); however, the GTV is equivalent
to the CTV in the case of prostate cancer. If the whole CTV receives a uniform dose D
i
, then the
TCP can be calculated as
(2)
where D
50
 is the dose leading to a 50% probability of local control, and γ
50
 is the normalized
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slope of the TCP versus dose curve at 50% TCP.(17,18) The probability to control a voxel with a
volume v
i
 receiving dose D
i
 is
(3)
To control the whole CTV, all voxels have to be controlled; therefore, the overall TCP for the
CTV is
(4)
For the critical organs, the D
eff
 was calculated using a power-law-based algorithm(19, 20):
(5)
The parameter n describes the strength of the volume effect. In the literature three different n
values have been reported that assume different volume dependence for rectal complications,
with n = 0.12,(12) n = 0.24,(10) and n = 0.746.(9) All the parameters used in the calculations are
shown in Table 2. The results of the simulations have been summarized as dose-population
histograms (DPH).(7) Similar to a DVH, each point on the cumulative DPH represents the
percentage of patients who receive at least a certain dose. Generally, dose in a DPH curve can
have a broad meaning, including minimum dose to the GTV, effective dose to an OAR, such as
in this paper, or any other dose chosen as a representative of outcome.
D. Plan evaluation
The rectum is considered to be the limiting organ for prostate dose escalation. For 70 Gy/35 fx,
as in our Reference Plan, the probability of rectal grade 2 bleeding, scored with the modified
RTOG-SOMA scale, is 12% to 14%.(1,22) We assumed that patients in the high-dose region of
the DPH curve are at higher risk to develop complications. We therefore strengthened the
acceptance criteria for dose escalation protocols. For each patient, we determined the D
eff
 on
the DPH curve that corresponded to 20% of patients in the Reference Plan as the dose leading
to acceptable risk. For the Escalated Plan to be acceptable, the risk should be lower. In this
study, less than 20% of patients treated with realignment must have their rectum D
eff
 lower or
equal to the risk level defined by the Reference Plan. This risk level is the baseline for accep-
tance of the Escalated Plan. Further, it connects our simulation results with the clinical
consequences.
E. Potential full 3D correction
In Chung et al.,(8) the online correction protocol only uses one lateral EPI to correct the AP and
SI geometric error. This allows for the realignment to be performed in a reasonable time frame
(around 8 min). Considering that the lateral shift of the prostate should be small compared with
AP and SI shifts, this procedure appears reasonable. However, the potential benefits of full 3D
correction have to be explored.
A full 3D realignment protocol is currently used in our center. To evaluate biological conse-
quences of this full 3D realignment quantitatively, we simulated reduction of uncertainties in
all dimensions. However, because only a small number of patients have been treated to date
with implanted fiducial markers at this center, the full 3D realignment data are presently insuf-
ficient to reliably establish uncertainties in 3D. Therefore, we manipulated the systematic and
random uncertainties in the lateral direction to make geometric error reduction consistent with
what was achieved for other directions. Instead of systematic uncertainty of 3.2 mm and ran-
dom uncertainty of 2.2 mm (see Table 1), we assumed 0.5 mm and 1.1 mm, respectively. This
simulation was performed for the Escalated Plan.
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III. RESULTS
A. Tumor control
All 4000 (20 treatment plan × 200 histories) virtual patients’ TCPs are shown in Fig. 1. The
Escalated Plan average TCP is 0.817, with a standard deviation of 0.011. In comparison, the
Reference Plan gives a mean TCP of 0.609 and a standard deviation of 0.014. This gain in
tumor control is consistent with parameter values used in our calculations, specifically, γ
50
 (see
Table 2). Values of the normalized slope for prostate cancer reported in the literature vary with
a range of 1.0 to 3.2(23) (intermediate risk prostate cancer). The impact of different parameters
has been investigated in our previous work.(9) While dose escalation is always beneficial, the
expected improvement in local control will of course be less if a shallower dose-response is
assumed.
Fig. 1. TCP histograms showing the Escalated Plan and the Reference Plan for all patient simulations
B. Rectal complications
The typical DPH curve for a single patient simulation is shown in Fig. 2. The vertical axis is the
percentage of all 200 histories, and the horizontal axis is the rectum D
eff
. The Reference Plan
(70 Gy with 10-mm margin and full uncertainty) leads to a broad distribution in D
eff
. In con-
trast, the DPH for the Escalated Plan (78 Gy with 5-mm margin and reduced uncertainty) is
steeper than the Reference Plan. If one DPH was fully “contained” in another, the preference
from a clinical perspective would be trivial. However, quite often the DPHs cross over at one
point. The point at which two DPHs cross strongly depends on the value of the parameter n
used in the D
eff
 calculation. In the region where D
eff
 is greater than the point of crossing, the
Escalated Plan always gives lower rectum dose as compared with the Reference Plan and vice
versa. If the point of crossing corresponds to a D
eff
 of minor clinical consequence, that is, rectal
toxicity, then the Escalated protocol would be superior and safer compared to the Reference
Plan.
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Fig. 2. Rectal dose population histograms (DPH) for one of the 20 patients (n = 0.746). The slope of the Reference Plan
curve is broad while that for the Escalated Plan curve is steep. Beyond the crossing, the Escalated Plan gives lower dose
to the rectum than the Reference Plan and vice versa.
Figure 3 shows the relationship between the location of crossing, presented as the vertical
axis value of the probability in the DPH at which the two plans intersect, and the static D
eff
 of
each patient from the Reference Plan as an index. The static D
eff
 is calculated without organ
motion simulation. In other words, the dose to the rectum for every fraction is delivered as
planned. As was addressed above, D
eff
 changes with n. The graph shows the proportion of
patients who would benefit if they were treated with the escalated dose, smaller margin, and
patient realignment, compared to the treatment with full uncertainty. If the point of crossing
falls on a clinically inconsequential D
eff
, we can assume that no patient will be subjected to a
higher risk of rectal toxicity compared to the Reference Plan. From the graph, the dose escala-
tion protocol reduces rectal dose to a large proportion of patients with large D
eff
, if we assume
rectum behavior is more parallel, that is, n = 0.746(9) or n = 0.24.(10) However, if more serial
behavior is assumed, n = 0.12,(12) some of the virtual patients have shown no obvious improve-
ment, exceeding the 20% risk level.
Fig. 3. The DPH probability at intersection point versus static D
eff
 plot for each patient with different n values. The
horizontal axis is the static D
eff
 of the Reference Plan. The vertical axis is the percentage in population.
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C. Look-up plots for static D
eff
 versus realistic D
eff
Look-up plots for the relationship between the D
eff
 from the planning DVH (static D
eff
) and the
realistic doses (blurred D
eff
) to patient accounting for geometric uncertainty in treatment, are
shown in Figs. 4(a), (b), and (c). The three possible parameters describing strength of volume
effects were modeled for two prescription doses. The median D
eff
 and 95% confidence limits
derived from the 200 histories are shown for the entire dataset. Variation in planned D
eff
 arises
from patient anatomy differences. These graphs illustrate the relationship between the dose
distribution calculated by the treatment-planning system and what is actually delivered to the
patient. These graphs also clearly show how potential benefits of applying tighter PTV mar-
gins and escalating the dose depend on the assumed strength of volume effects.
Fig. 4(a). Static D
eff
 of the Reference Plan versus the blurred D
eff
 of the Reference Plan (left) and the Escalated Plan (right)
for n = 0.12. The blurred D
eff
, due to geometric uncertainty associated in treatment, is shown as a median value and the
95% confidence limits. The dashed line shows equal static D
eff
 and blurred D
eff
 as a reference.
Fig. 4(b). Static D
eff
 of the Reference Plan versus the blurred D
eff
 of the Reference Plan (left) and the Escalated Plan (right)
for n = 0.24. The blurred D
eff
, due to geometric uncertainty associated in treatment, is shown as a median value and the
95% confidence limits. The dashed line shows equal static D
eff
 and blurred D
eff
 as a reference.
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Fig. 4(c). Static D
eff
 of the Reference Plan versus the blurred D
eff
 of the Reference Plan (left) and the Escalated Plan (right)
for n = 0.746. The blurred D
eff
, due to geometric uncertainty associated in treatment, is shown as a median value and the
95% confidence limits. The dashed line shows equal static D
eff
 and blurred D
eff
 as a reference.
D. Potential 3D full correction
The results with additional lateral realignment show that the calculated average increase in the
lowest TCP (considering the worst scenario) among the 20 patients is 0.83%, shown in Fig. 5.
The D
eff
 to rectum and bladder has no significant change with 3D full correction for all pos-
sible n values.
Fig. 5. TCP graph showing mean values for 2D correction and potentially 3D full correction with the 95% confidence
limits for the 20 patients
IV. DISCUSSION
The intuitive thinking for isotoxicity or toxicity-free dose escalation protocol is to reduce the
geometric uncertainties, and then reduce the PTV margins. This has been pointed out by au-
thors who presented results of prostate intensity-modulated radiotherapy (IMRT) or stereotactic
radiation therapy for prostate cancer.(21,22,24-26) This drives image-guided radiation therapy to
be the next step in radiation therapy. Patient realignment using internal fiducial markers and
EPI has proven to be a reliable approach. Uncertainty control by EPI applied to prostate IMRT
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has been reported in the literature.(21,22) Dose escalation protocols were suggested with patient
realignment and margin reduction being an integral part of the protocol.
A. Geometric uncertainties
This work is intended to investigate the dose escalation protocol using Princess Margaret
Hospital’s previously published online patient realignment protocol.(8) Therefore, the geomet-
ric uncertainties for patient realignment are taken from their publication.(8) The geometric
uncertainties for current treatment procedure, no realignment, are taken from the study of van
Herk et al.(7) The data are believed to represent the clinical situation at our center because we
have the same patient management: full bladder without rectum balloon. The magnitude of
geometric uncertainties will affect the simulation results. However, since we follow the clini-
cal data, our results reveal the clinical consequences.
In this study, we simulated the organ motion without organ deformation. The rectum and the
bladder are considered to be the most deformable organs instead of the prostate. If the organ
deformation had been considered, the biological consequences of the dose escalation protocol
may have been affected. Incorporating organ deformation is planned for our future studies.
B. Patient anatomy
For dose to critical organs, there are two factors that contribute to the dose variation among the
population: geometric errors, which will “blur” the dose distribution for a single patient, and
the patient’s anatomy. Some patients may receive higher doses to a critical organ because of
the relative positions of the critical organ and the prostate. This has been offset to some extent
by choosing alternative beam arrangements, for example, IMRT versus four-field. In clinical
practice, plan acceptance depends on the dose distribution calculated for the planning CT. In
this study, we calculated look-up plots that allow us to estimate more realistic dose variation
when uncertainties are full (no realignment) and reduced (patient realigned prior to every frac-
tion). These look-up plots can be used to identify patients who may be suitable for dose
escalations without excess risk of rectal complications.
C. Rectal complications
In our study, we considered gastrointestinal complications only. Genito-urinary (GU) compli-
cations were not investigated because they are difficult to analyze, hematuria may originate
from either the bladder or the urethra, and there is no consistent bladder or urethral DVH
correlation for GU complication. Because of the reduced PTV margin, better sparing of sur-
rounding organs, including the bladder, can be achieved. Although quantification of biological
consequences of this margin reduction in terms of GU complications is associated with signifi-
cant uncertainties, one would still speculate that there is an advantage in reducing radiation
dosage received by the bladder. In terms of erectile dysfunction, again, one would expect an
advantage with a tighter margin and thus less radiation dosage to the penile bulb, and perhaps
better preservation of sexual function. But without extensive supporting data showing there is
a strong correlation of penile bulb dosimetry and erectile dysfunction, we did not analyze this
effect, although this remains a very interesting research question.
For rectal complications, we use the D
eff
 as our evaluation scale. The D
eff
 was calculated by
reducing rectal DVH to one value. In this procedure an n factor was used, which describes the
strength of the rectum volume dependence. A larger n value corresponds to more parallel dose-
volume dependence. However, currently there is no consensus about this value.
The value of the parameter describing the strength of volume effects (n = 0.12(12)) reported
by Burman et al. was obtained from the TD5/5 and TD50/5 data given by Emami et al.(11) Due
to the lack of clinical evidence for partial organ tolerance doses, expert opinion was used.
Burman et al. acknowledged that “To determine the volume dependence parameter, n, for or-
gans with insufficient data, a best clinical estimate was made by a group of investigators.”
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Therefore, n = 0.12 originates from professional opinion rather than dose-volume based clini-
cal data.
The n = 0.746(9) reported by the M.D. Anderson hospital group was based on clinically
observed complications and planning DVHs. The study group comprised 128 patients, but they
excluded patients with hemorrhoids to obtain the above n factor, a further reduction to 84
patients. The prescription dose was the same for all patients: 46 Gy with a four-field box tech-
nique followed by a six-field arrangement to boost the total target dose to 78 Gy.
The latest data, n = 0.24,(10) are given by a multicenter study performed in Italy. The patient
population was 547. Different prescription doses were used, ranging from 64 Gy to 79.2 Gy.
Presently, this is the most broadly based study both in terms of sample size and variation in
dose-volume distributions.
From the clinical data, it appears that the rectum behavior is not as serial as we long be-
lieved, suggesting that an n = 0.12 value may not be appropriate. Some hints for this were
provided by clinical practice using 3D CRT. The Memorial Sloan-Kettering Cancer Center (27)
reported that with a prescription dose of 81 Gy and a 1.0-cm margin PTV, except at the pros-
tate–rectum interface, where a 0.6-cm margin was used, rectal grade 2 or higher (RTOG scale)
complication rate was 16.5%. In the M.D. Anderson report,(28) a 78 Gy prescription dose with
a tighter margin was used: “the block edge was placed 1.25 cm to 1.5 cm around the CTV in the
anterior and inferior directions and 0.75 cm to 1.0 cm in the posterior and superior directions.”
The rectal grade 2 or higher (RTOG scale) complication rate was 21%. This clinical evidence
shows that there is no dramatic increase in rectal complications as the serial model predicted.
According to the Italian multicentric analysis data(10) for rectum (n = 0.24), dose escalation
with patient realignment not only improves the local control, but also gives a lower probability
of rectal complications; see Fig. 3.
Margin reduction and dose escalation, according to our results, can be safely achieved with
realignment. However, rectal volume effects put strong constraints on this. Therefore, prostate
dose escalation studies have to include collection of full dose-volume data for OARs and pos-
sibly dose-rectal wall data.
D. Potential full 3D correction
From Fig. 5, for most of the patients, a full 3D correction gives better local control than 2D
correction. However, in terms of average TCP, the increase is less than 1%. For D
eff
 to rectum,
the 3D correction does not show an advantage compared to the 2D correction. Considering the
extra workload of lateral geometric uncertainty correction, correction of lateral geometric un-
certainty may provide little clinical benefit.
V. CONCLUSION
According to our analysis of the rectum dose and assuming a parallel behavior for rectal com-
plications for patients treated with prostate fields only, prescription dose can be escalated from
70 Gy/35 fx to 78 Gy/39 fx with reduced 3D PTV margin from 10 mm to 5 mm if patient
repositioning by EPI and internal fiducial markers is used. Current data support more parallel
response for rectal bleeding. If this is confirmed, further escalation might be achievable. Look-
up plots for static D
eff
 versus realistic D
eff 
were generated. They can be used to improve the
clinical decision process for plan evaluation and acceptance. Full 3D correction is not substan-
tially superior to the 2D correction.
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